Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Ticker
$ABVX
Sector
Primary listing
Employees
69
Headquarters
Website
Abivax SA ADS Metrics
BasicAdvanced
$7.2B
-
-$3.60
0.13
-
Price and volume
Market cap
$7.2B
Beta
0.13
52-week high
$98.64
52-week low
$4.77
Average daily volume
980K
Financial strength
Current ratio
0.766
Quick ratio
0.674
Long term debt to equity
-103.281
Total debt to equity
-204.449
Interest coverage (TTM)
-13.11%
Profitability
EBITDA (TTM)
-216.576
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,244.03%
Operating margin (TTM)
-3,099.50%
Revenue per employee (TTM)
$104,990
Management effectiveness
Return on assets (TTM)
-57.74%
Return on equity (TTM)
-499.78%
Valuation
Price to revenue (TTM)
854.313
Price to book
-107.28
Price to tangible book (TTM)
-70.65
Price to free cash flow (TTM)
-37.84
Free cash flow yield (TTM)
-2.64%
Free cash flow per share (TTM)
-2.506
Growth
Revenue change (TTM)
-33.90%
Earnings per share change (TTM)
-1.57%
3-year revenue growth (CAGR)
39.30%
10-year revenue growth (CAGR)
28.28%
3-year earnings per share growth (CAGR)
3.18%
10-year earnings per share growth (CAGR)
9.86%
Bulls say / Bears say
Obefazimod’s 50 mg once-daily dose achieved a placebo-adjusted clinical remission rate of 16.4% at week 8 in the pooled Phase 3 ABTECT-1 and ABTECT-2 trials, meeting the FDA’s primary and key secondary endpoints.
In July 2025, Abivax completed a $747.5 million public offering—including full exercise of the underwriters’ option—raising approximately $700.3 million in net proceeds and extending its cash runway into the fourth quarter of 2027.
The strong Phase 3 results have drawn significant analyst and acquisition interest; Leerink Partners raised its price target from $20 to $74 and cited potential M&A suitors including Merck, Roche, Pfizer, and Eli Lilly.
Abivax reported an operating loss of €93.7 million in the first half of 2025, up from €80.0 million in the same period of 2024, due mainly to €77.9 million in research and development expenses, reducing its cash balance to €60.9 million as of June 30, 2025.
Obefazimod’s regulatory path depends on results from the 44-week maintenance phase, expected in the second quarter of 2026; negative or delayed data could postpone the planned NDA submission in the second half of 2026, increasing risks to both valuation and approval timelines.
As a pure clinical-stage biotech, Abivax posted just $7.07 million in revenue over the last twelve months with a net loss of $229.46 million, highlighting its lack of marketed products and reliance on future pipeline success.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Abivax SA ADS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $7.2B as of October 28, 2025.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of October 28, 2025.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.